MedPath

Rocuronium

Generic Name
Rocuronium
Drug Type
Small Molecule
Chemical Formula
C32H53N2O4
CAS Number
143558-00-3
Unique Ingredient Identifier
WRE554RFEZ

Overview

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Background

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Indication

For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Conditions

  • Muscle fasciculation caused by succinylcholine

Clinical Trials

Not Applicable
Completed
Posted: 2020/08/12
Sponsor:
National Cancer Inst...
Phase 4
Completed
Posted: 2019/09/26
Sponsor:
Wahba bakhet
Not Applicable
Completed
Posted: 2019/07/29
Sponsor:
Medical University o...

FDA Approved Products

Rocuronium Bromide
Manufacturer:Mylan Institutional LLC
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2017/02/07
NDC:67457-228
ROCURONIUM BROMIDE
Manufacturer:Lupin Pharmaceuticals, Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2023/12/15
NDC:70748-348
Rocuronium
Manufacturer:Piramal Critical Care Inc
Route:INTRAVENOUS
Strength:50 mg in 5 mL
Approved: 2023/12/21
NDC:66794-228
rocuronium bromide
Manufacturer:Hospira, Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2023/08/29
NDC:0409-5160
rocuronium bromide
Manufacturer:Hospira, Inc.
Route:INTRAVENOUS
Strength:10 mg in 1 mL
Approved: 2023/08/29
NDC:0409-1403

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath